Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
Phase 1
Completed
- Conditions
- Biological Availability
- Interventions
- Drug: Desogestrel/ CerazetteDrug: Norethindrone/ NoridayDrug: levonorgestrel/ MicrolutDrug: Dienogest/ VisanneDrug: Drospirenone, Ethinylestradiol/ YasminDrug: Midazolam/ Midazolam-ratiopharm
- Registration Number
- NCT03353857
- Lead Sponsor
- Bayer
- Brief Summary
Quantify the effect of a probe CYP3A4 inducer (Rifampicin) on the pharmacokinetics of levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 68
Inclusion Criteria
-
Healthy female subject based on a complete medical history, physical examination, ECG, and clinical laboratory tests
-
Age: 45 to 70 years (inclusive) at the first screening visit
-
Minimum body weight 50 kg with Body mass index (BMI) above or equal to 18.5 kg/m², and below or equal to 30 kg/m² at the first screening visit
-
Postmenopausal state, revealed indicated by either:
- medical history, if applicable (natural menopause at least 12 months prior to first study drug administration, for women younger than 60 years confirmed by follicle stimulating hormone (FSH) >40 IU/L AND estradiol ≤ 20 pg/mL; or
- surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration)
Exclusion Criteria
- Relevant diseases within the last 4 weeks prior to the first study drug administration, i.e. any disease requiring treatment by a health-care provider
- Febrile illness within 1 week before the first study drug administration
- Known severe allergies, non-allergic drug reactions, or multiple drug allergies
- Presence or history of thrombosis, thrombophlebitis, thromboembolic diseases of veins and/or arteries, e.g. deep vein thrombosis, stroke, myocardial infarction, pulmonary embolism, transient ischemic attack, angina pectoris
- Presence or history of conditions that increase the risk of thromboembolic diseases, e.g. disturbances of the coagulation system, thromboembolic diseases in close relatives at age ≤50 years], valvular heart disease, atrial fibrillation, cardiac dysfunction)
- Presence, history, or suspected presence of malignant tumors or tumors of the liver and pituitary
- Presence or history of liver disease e.g. disturbances of the bilirubin excretion (Dubin-Johnson and Rotor syndromes), cholecystectomy ; cholestasis, idiopathic icterus or pruritus during a previous pregnancy or estrogen-progestogen treatment
- Relevant kidney diseases or renal injury associated with multisystem diseases/disorders, e.g. glomerulonephritis systemic lupus erythematous, diabetic nephropathy. A history of a single episode of uncomplicated nephrolithiasis does not prevent participation
- Known metabolic disorder, e.g. diabetes mellitus, severe hypertriglyceridemia
- Migraine with neurologic symptoms
- Clinically significant depression, current or in the last year
- Known current thyroid disorders which require treatment. Subjects with an euthyroid struma who do not need any treatment can participate.
- Chronic respiratory insufficiency
- History of porphyria
- Contraindications for midazolam, e.g. myasthenia gravis, and sleep apnea
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description norethindrone Midazolam/ Midazolam-ratiopharm norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. desogestrel Desogestrel/ Cerazette desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. desogestrel Midazolam/ Midazolam-ratiopharm desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. norethindrone Norethindrone/ Noriday norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. dienogest Midazolam/ Midazolam-ratiopharm dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. levonorgestrel levonorgestrel/ Microlut levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. levonorgestrel Midazolam/ Midazolam-ratiopharm levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. dienogest Dienogest/ Visanne dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. Drospirenone/ ethinylestradiol Drospirenone, Ethinylestradiol/ Yasmin drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. Drospirenone/ ethinylestradiol Midazolam/ Midazolam-ratiopharm drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. levonorgestrel Rifampicin levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. norethindrone Rifampicin norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. desogestrel Rifampicin desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. dienogest Rifampicin dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29. Drospirenone/ ethinylestradiol Rifampicin drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
- Primary Outcome Measures
Name Time Method Area under the plasma concentration time curve from zero to infinity (AUC) of levonorgestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Maximum plasma concentration (Cmax) of etonogestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Area under the plasma concentration time curve from zero to infinity (AUC) of dienogest in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Area under the plasma concentration time curve from zero to infinity (AUC) of norethindrone in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Maximum plasma concentration (Cmax) of levonorgestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Maximum plasma concentration (Cmax) of norethindrone in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Area under the plasma concentration time curve from zero to infinity (AUC) of etonogestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Maximum plasma concentration (Cmax) of dienogest in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Maximum plasma concentration (Cmax) of drospirenone (+EE) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Area under the plasma concentration time curve from zero to infinity (AUC) of ethinylestradiol (+DRSP) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Maximum plasma concentration (Cmax) of ethinylestradiol (+DRSP) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Area under the plasma concentration time curve from zero to infinity (AUC) of drospirenone (+EE) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Area under the plasma concentration time curve from zero to infinity (AUC) of midazolam in combination with the hormonal contraceptive only (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3 Maximum plasma concentration (Cmax) of midazolam in combination with the hormonal contraceptive only (without RIF) and in combination with 10 mg/d and 600 mg/d RIF Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
CRS Clinical-Research-Services Mannheim GmbH
🇩🇪Mannheim, Baden-Württemberg, Germany
CRS Clinical-Research-Services Mönchengladbach GmbH
🇩🇪Mönchengladbach, Nordrhein-Westfalen, Germany